While we enthusiastically wax prophetic on possible buyout prices, the SP continues to drop.
As someone holding more than 500,000 shares and warrants, as a result of participating in a number of Paulson raises, this is very discouraging.
With great results in the combo trial, I had expected a huge bump in the share price, rather than a precipitous decline.
That being said, I remain confident in the science, and eventual outcome for CYDY.
Perhaps the impending announcement of results from the very small (10 person) GVHD trial will light a fire under the stock.
Or perhaps the SP will reflect the true value of the company when announcements are made regarding the low viral load of patients continuing in the combo trial, or positive results from the mono trial.
At some point, the SP will fairly reflect the value of PRO 140.
However, today I remain disappointed in the muted reaction to the combo trial results that should have catapulted the SP to new highs.
LM
Market Data 
Markets 
AI
